Clinical application of exosomal miRNA as biomarker in breast cancer

Abstract

Cao Lixia, Shi Zhendong, Liu Jingjing, Zhang Jin. Clinical application of exosomal miRNA as biomarker in breast cancer[J]. Journal of International Oncology, 2019, 46(7): 423-426.

［1］ Harbeck N, Gnant M. Breast cancer［J］. Lancet, 2017, 389(10074): 11341150. DOI: 10.1016/S01406736(16)318918. ［2］ Rugo HS, Olopade OI, DeMichele A, et al. Adaptive randomization of veliparibcarboplatin treatment in breast cancer［J］. N Engl J Med, 2016, 375(1): 2324. DOI: 10.1056/NEJMoa1513749. ［3］ Joyce DP, Kerin MJ, Dwyer RM. Exosomeencapsulated microRNAs as circulating biomarkers for breast cancer［J］. Int J Cancer, 2016, 139(7): 14431448. DOI: 10.1002/ijc.30179. ［4］ Sun Y, Liu J. Potential of cancer cellderived exosomes in clinical application: a review of recent research advances［J］. Clin Ther, 2014, 36(6): 863872. DOI: 10.1016/j.clinthera.2014.04.018. ［5］ Lee JH, Kim JA, Jeong S, et al. Simultaneous and multiplexed detection of exosome microRNAs using molecular beacons［J］. Biosens Bioelecton, 2016, 86: 202210. DOI: 10.1016/j.bios.2016.06.058. ［6］ Hellwinkel JE, Redzic JS. Gliomaderived extracellular vesicles selectively suppress immune responses［J］. Neuro Oncol, 2016, 18(4): 497506. DOI: 10.1093/neuonc/nov170. ［7］ Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: celltocell mediators of metastasis［J］. Cancer Cell, 2016, 30(6): 836848. DOI: 10.1016/j.ccell.j.ccell.2016.10.009. ［8］ Kalluri R. The biology and function of exosomes in cancer［J］. J Clin Invest, 2016, 126(4): 12081215. DOI: 10.1172/JCI81135. ［9］ Frassanito MA, De Veirman K, Desantis V. Halting prosurvival autophagy by TGFβ inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients［J］. Leukemia, 2016, 30(3): 640648. DOI: 10.1038/leu.2015.289. ［10］ Jia Y, Chen Y, Wang Q, et al. Exosome: emerging biomarker in breast cancer［J］. Oncotarget, 2017, 8(25): 4171741733. DOI: 10.18632/oncotarget.16684. ［11］ Wang X, Zhang H, Bai M, et al. Exosomes serve as nanoparticles to deliver antimiR214 to reverse chemoresistance to cisplatin in gastric cancer［J］. Mol Ther, 2018, 26(3): 774783. DOI: 10.1016/j.ymthe. ［12］ Wang T, Fang L, Zhao F, et al. Exosomes mediate intercellular transmission of porcine reproductive and respiratory syndrome virus［J］. J Virol, 2018, 92(4). pii: e0173417. DOI: 10.1128/JVI.0173417. ［13］ Moore C, Kosgodage U, Lange S, et al. The emerging role of exosome and microvesicle (EMV) based cancer therapeutics and immunotherapy［J］. Int J Cancer, 2017, 141(3): 428436. DOI: 10.1002/ijc.30672. ［14］ Gorski SA, Vogel J, Doudna JA. RNAbased recognition and targeting: sowing the seeds of specificity［J］. Nat Rev Mol Cell Biol, 2017, 18(4): 215228. DOI: 10.1038/nrm.2016.174. ［15］ Ohno S, Kuroda M. Exosomemediated targeted delivery of miRNAs［J］. Methods Mol Biol, 2016, 1448: 261270. DOI: 10.1007/9781493937530_19. ［16］ Hannafon BN. Plasma exosome microRNAs are indicative of breast cancer［J］. Breast Cancer Res, 2016, 18(1): 90. DOI: 10.1186/s130580160753x. ［17］ Naughton E. Exosomeencapsulated microRNA451a as a circulating biomarker for breast cancer［J］. Ir J Med Sci, 2017, 186 (Suppl 1): S1S39. DOI: 10.1007/s1184501615325. ［18］ Stevic I, Müller V, Weber K, et al. Specific microRNA signatures in exosomes of triplenegative and HER2positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial［J］. BMC Med, 2018, 16(1): 179. DOI: 10.1186/s129160181163y. ［19］瞿望. 采用AT方案新辅助化疗的Luminal A型乳腺癌患者血浆外泌体microRNA特征研究［D］. 北京: 北京协和医学院中国医学科学院, 2017. ［20］ Zhao L, Liu W, Xiao J, et al. The role of exosomes and “exosomal shuttle microRNA” in tumorigenesis and drug resistance［J］. Cancer Lett, 2015, 356(2 Pt B): 339346. DOI: 10.1016/j.canlet.2014.10.027. ［21］ Eichelser C, Stuckrath I, Muller V, et al. Increased serum levels of circulating exosomal microRNA373 in receptornegative breast cancer patients［J］. Oncotarget, 2014, 5(20): 96509663. DOI: 10.18632/oncotarget.2520. ［22］ Yoshikawa M. Exosomeencapsulated microRNA2233p as a minimally invasive biomarker for the early detection of invasive breast cancer［J］. Oncol Lett, 2018, 15(6): 95849592. DOI: 10.3892/ol.2018.8457. ［23］ O′Brien K, Lowry MC. miR134 in extracellular vesicles reduces triplenegative breast cancer aggression and increases drug sensitivity［J］. Oncotarget, 2015, 6(32): 3277432789. DOI: 10.18632/oncotarget.5192. ［24］ Hu W, Tan C, He Y, et al. Functional miRNAs in breast cancer drug resistance［J］. Onco Targets Ther, 2018, 11: 15291541. DOI: 10.2147/OTT.S152462. ［25］ Yardley DA. Visceral disease in patients with metastatic breast cancer: efficacy and safety of treatment with ixabepilone and other chemotherapeutic agents［J］. Clin Breast Cancer, 2010, 10(1): 6473. DOI: 10.3816/CBC.2010.n.009. ［26］ Zhou W, Fong MY, Min Y, et al. Cancersecreted miR105 destroys vascular endothelial barriers to promote metastasis［J］. Cancer Cell, 2014, 25(4): 501515. DOI: 10.1016/j.ccr.2014.03.007. ［27］ Singh R, Pochampally R, Watabe K, et al. Exosomemediated transfer of miR10b promotes cell invasion in breast cancer［J］. Mol Cancer, 2014, 13: 256. DOI: 10.1186/1476459813256. ［28］ Sueta A, Yamamoto Y, Tomiguchi M, et al. Differential expression of exosomal miRNAs between breast cancer patients with recurrence and norecurrence［J］. Oncotarget, 2017, 8(41): 6993469944. DOI: 10.18632/oncotarget.19482.

[1]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu.Advances in immunotherapy for breast cancer[J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Xie Shuping, Sun Yahong, Wang Chao.Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 157-165.
[5]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180.
[6]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[7]	Liu Bohan, Huang Junxing.Research progress of liquid biopsy technology in esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2024, 51(2): 105-108.
[8]	Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82.
[9]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[10]	Wang Jing, Xu Wenting.Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm[J]. Journal of International Oncology, 2023, 50(9): 520-526.
[11]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying.Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients[J]. Journal of International Oncology, 2023, 50(9): 527-531.
[12]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng.Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway[J]. Journal of International Oncology, 2023, 50(8): 449-456.
[13]	Pan Shulan, Liu Chang, He Ping.Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer[J]. Journal of International Oncology, 2023, 50(8): 457-462.
[14]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.Current status of research on exosomes in malignancies[J]. Journal of International Oncology, 2023, 50(8): 484-488.
[15]	Wang Wende, Zeng De.Research progress on the mechanism of endocrine therapy resistance for breast cancer[J]. Journal of International Oncology, 2023, 50(6): 352-356.

Clinical application of exosomal miRNA as biomarker in breast cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments